Unlocking Safe & Potent T-Cell Engagers by Applying Rational Design Principles to Maximise Efficacy & Minimise Toxicity

• Tuning affinity, valency and format to efficiently form immune synapse
• Engineering CD8 T-cell selectivity to minimise CRS and ICANS without compromising therapeutic potency
• Presenting pre-clinical data on leading programs entering clinical trial

Speakers:

Marc Lenoir

Associate Director, Biologics Engineering

AstraZeneca